Pancreatic cancer pill erases tumours in 1 in 12 patients, trial finds
A daily pill called daraxonrasib made pancreatic tumours undetectable in one in 12 patients with advanced disease, according to early trial results presented in Barcelona. Doctors call it the closest thing to a cure they have seen for a cancer that kills half of patients within three months.
- Original source: theguardian.com.
- The source published it on Nov 20, 2026 at 9:36 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
A pill called daraxonrasib shrank or wiped out tumours in just over 60% of 61 patients with advanced pancreatic cancer that had spread to other organs, doctors reported at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. In about 8% of patients — one in 12 — no cancer was detectable on CT scans. Tumours stopped growing in 90% of the group, and patients were tracked for an average of 18 months.
The survival numbers stand out against the usual picture. A year after starting treatment, 76.6% of patients were still alive, compared with the 40-45% who typically survive that long on chemotherapy alone. Half of everyone diagnosed with pancreatic cancer dies within three months, and only about 3% of patients live five years once the disease spreads. It has the lowest survival rate of any common cancer in the UK.
Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York who presented the findings, called it “this is the closest to cure” and said he had never seen so many tumours vanish in patients whose cancer had spread. “We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival,” he said. He described an average 18-month follow-up in which the disease simply disappears from a scan as “closest to complete remission.”
The drug is a KRAS inhibitor, designed to latch onto and switch off mutations that drive tumour growth in most pancreatic cancers. That same mechanism could apply far beyond the pancreas, because dozens of other cancers carry similar mutations. Park cautioned that the pill is not yet a cure and that nobody knows how long it can hold the disease back; longer studies are planned to see whether any cancers can be pushed into full remission.
Michelle Mitchell, chief executive of Cancer Research UK, urged caution but did not hide her enthusiasm. “This is the biggest leap forward we’ve seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult-to-treat cancers,” she said, adding that the results raise the possibility of treating other cancers with Kras gene mutations. She also noted that more trials are needed before the treatment can be assessed for NHS use, and that pancreatic cancer survival overall remains very low.
Topicsdaraxonrasib · Dr Wungki Park · Memorial Sloan Kettering Cancer Center · Michelle Mitchell · Cancer Research UK · EORTC-NCI-AACR Symposium · Barcelona
Source: theguardian.com
Written by AI from verified reporting.
More stories
- Health & science wired.com 0 viewsEl Niño Pushes California's Coastal Waters Off the Charts, and the Storms Are Following
- Health & science biobuzz.io 0 viewsFDA approves AstraZeneca's once-weekly Klygefa for generalised myasthenia gravis
- Health & science pluang.com 1 viewGalleri wins FDA panel nod as GRAIL chases first multi-cancer screening approval
- Health & science techtimes.com 2 sources 2 viewsFDA Clears Regeneron's Quarterly RNA Shot Livsayis for Myasthenia Gravis

